Cocaine-induced Psychosis and Brain-derived Neurothrophic Factor in Patients with Cocaine Dependence : Report of Two Cases by Roncero, Carlos et al.
109
Case Report
http://dx.doi.org/10.9758/cpn.2016.14.1.109 pISSN 1738-1088 / eISSN 2093-4327
Clinical Psychopharmacology and Neuroscience 2016;14(1):109-113 Copyrightⓒ 2016, Korean College of Neuropsychopharmacology
                      
Received: June 23, 2015 /Revised: July 31, 2015
Accepted: August 17, 2015
Address for correspondence: Carlos Roncero, MD, PhD
Department of Psychiatry, Vall d’Hebron University Hospital, 
Passeig Vall d’Hebron, 119-129, 08035 Barcelona, Spain 
Tel: +34-93-489-42-95, Fax: +34-93-489-45-87
E-mail: croncero@vhebron.net
 This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cocaine-induced Psychosis and Brain-derived Neurothrophic Factor in Patients 
with Cocaine Dependence: Report of Two Cases 
Carlos Roncero1,2,3, Raul Felipe Palma-Álvarez2, Elena Ros-Cucurull1,2,3, Carmen Barral1,2, Begoña Gonzalvo2, 
Margarida Corominas-Roso2, Miguel Casas2,3, Lara Grau-López1,2,3
1Addictions and Dual Diagnosis Unit, Vall d’Hebron University Hospital-Public Health Agency of Barcelona (ASPB), Centro de Investigación 
Biomédica en Red de Salud Mental (CIBERSAM), 2Department of Psychiatry, Vall d’Hebron University Hospital, CIBERSAM, 3Department 
of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
Brain-derived neurotrophic factor (BDNF) is linked to numerous brain functions. In addition, BDNF alterations contribute to neuro-
logical, mental, and addictive disorders. Cocaine dependence has received much attention recently due to its prevalence and 
psychological effects. Symptoms of psychosis are one of the most serious adverse events precipitated by cocaine use. It is 
particularly important to identify patients at risk of developing cocaine-induced psychosis (CIP). We described two cases of 
patients with cocaine dependence who presented with CIP and had changes in their BDNF levels during the psychotic episode. 
BDNF levels were initially low in both patients, and then decreased by more than 50% in association with CIP. The relationship 
between BDNF and psychosis is described in the literature. These cases revealed that BDNF levels decreased during a CIP 
episode and, thus, it is necessary to investigate BDNF and its relationship with CIP further.
KEY WORDS: Cocaine-induced psychosis; Cocaine dependence; Brain-derived neurotrophic factor; Biological marker; 
Psychosis. 
INTRODUCTION
Brain-derived neurotrophic factor (BDNF) is a neuro-
trophin involved in neurodevelopment, neuroprotection, 
synapse regulation, and learning and memory.1-4) BDNF 
interacts with dopamine, glutamine, and other neuro-
transmitter systems.1,5) Because of those interactions, 
BDNF has also been proposed as an illness and prognostic 
marker for several neurologic, mental, and addictive 
disorders.2-4,6,7) Many studies have indicated a correlation 
between schizophrenia and psychotic episodes with de-
creased BDNF levels (including two meta-analyses)1,8-11); 
this relationship is probably mediated by alterations in 
synaptic function and connectivity.9) It is known that 
BDNF is decreased during a patient’s first psychotic epi-
sode;10,11) this decrease becomes more marked with dis-
ease progression.8) Additionally, an age-related reduction 
in BDNF has been observed in blood.9) Antipsychotics 
and antidepressants can affect BDNF levels; however, 
findings regarding the effects of antipsychotics are equi-
vocal. Some investigations showed that BDNF levels dif-
fered following treatment with typical versus atypical 
antipsychotics.2) Evidence suggests that typical anti-
psychotics decrease BDNF levels, but mixed results have 
been found regarding atypical antipsychotics.2) 
BDNF has recently been associated with cocaine-in-
duced psychosis (CIP). The term CIP is used to describe 
symptoms of psychosis (suspiciousness, paranoia, delu-
sions, and hallucinations) that are precipitated by cocaine 
use.5,12) For this reason, BDNF levels could act as a bio-
logical marker of psychosis in patients with cocaine 
dependence. Psychotic symptoms have been reported in 
more than 50% of patients with cocaine dependence; this 
percentage ranges from 48% to 88% depending on the 
study variables.13) 
Numerous risk factors are associated with CIP,3,12,13) in-
cluding age at first use, amount of substance, route of ad-
ministration, use of other substances, personal vulner-
ability, and comorbid psychiatric disorders.12,13) Interest-
ingly, some studies of patients with chronic cocaine addic-
tion also reported low levels of BDNF.3) However, there is 
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no consensus regarding the role of BDNF level on cocaine 
use relapse.14) There are few studies of the relationship be-
tween BDNF and CIP. To the best of our knowledge, only 
one study investigated patients with CIP and their BDNF 
levels. That study concluded that BDNF could play a role 
in psychotic symptoms in cocaine users because BDNF 
levels did not rise after withdrawal in patients with CIP 
compared with patients without a history of CIP.5) This 
conclusion was reached following an observed correlation 
between a decreased BDNF level and CIP, which is sim-
ilar to findings in patients with schizophrenia and other 
psychosis.5) In this context, BDNF and other biological 
markers might be useful in identifying patients with a vul-
nerability for CIP and may also be a prognostic factor.5) 
Not only do neuropsychiatric diseases alter BDNF lev-
els, but many other conditions such as diet, exercise, nic-
otine, and caffeine use alter BDNF levels as well. Some 
research suggests that diet and exercise could interact with 
BDNF expression.15,16) Caffeine increased BDNF ex-
pression in some animal models,17,18) as did nicotine19); 
however, not all investigations have come to this con-
clusion.19)
We present two patients with cocaine dependence and 
CIP who were evaluated and included in an independent 
clinical trial conducted by the Psychiatry Department at 
the Vall d’Hebron University Hospital (Barcelona, Spain). 
These patients were hospitalized for cocaine detox-
ification, and serum BDNF levels were measured at the 
beginning of hospitalization as well as 12 days later. Both 
patients presented with psychotic symptoms during hospi-
talization, and were thus excluded from the clinical trial. 
Interestingly, BDNF levels further decreased during the 
psychotic episode compared with the levels found upon 
initial measurement.
CASE
The two patients were participants of a clinical trial that 
was conducted by the Psychiatry Department at the Vall 
d’Hebron University Hospital in which a combination of 
caffeine, biperiden, and placebo was evaluated as a treat-
ment for cocaine dependence (www.clinicaltrials.gov 
identifier: NCT00495092). That trial was approved by 
The Clinical Research Ethics Committee of the Vall 
d’Hebron University Hospital. All patients signed an in-
formed consent form and agreed to be included in the 
study. Both individuals described earlier were excluded 
from that trial because they presented with psychotic 
symptoms during the study. 
During their hospital stay, the patients were in a locked 
unit with no substance access and restrictions on visitation. 
They were detoxicated, and drug testing was performed 
during their hospitalization. The patients were seen every 
day by the psychiatrist who performed their initial clinical 
assessment and diagnosis (according the Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition 
[DSM-IV] criteria). As part of the original trial, they re-
ceived caffeine or placebo; the general conditions were 
the same for all inpatients (e.g., diet, exercise). 
As per the protocol, two blood samples were collected 
from each patient in the original trial: one at the beginning 
and the other 12 days after the first sample was taken. No 
other samples were collected for BDNF assay. Serum 
BDNF was determined by sampling 8 ml of peripheral 
blood between 10:00 am and 12:00 am to avoid circadian 
interference. The samples were kept in anticoagulant-free 
tubes for 2 hours at 4oC. Serum BDNF was measured us-
ing a sandwich enzyme-linked immunosorbent (ELISA) 
system for quantitative protein measurement (Aushon 
Biosystems, Billerica, MA, USA). 
Case 1
A 25-year-old male came to the detoxification unit to 
participate in the clinical trial. His last cocaine use was 24 
hours prior to hospitalization. He presented with simple 
reference delusions with behavioral repercussion; fur-
thermore, he had auditory hallucinations and some simple 
visual hallucinations. This psychotic pattern developed on 
day 5 after unit admission, and the episode duration was 
approximately 4 days. The patient did not have other men-
tal nor neurological symptoms (e.g., his consciousness 
was never compromised, and no attention deficits were 
observed). This episode was investigated, and no meta-
bolic etiology was established. A benzodiazepine was 
prescribed. On the first day of hospitalization, his initial 
BDNF level was measured: the BDNF level was low 
(70.94 ng/ml), and this level decreased further 12 days lat-
er (49.05 ng/ml). 
The patient’s psychiatric history included a major de-
pressive (MD) episode, diagnosed 6 years prior, with total 
recovery. Cocaine and nicotine dependence were diag-
nosed before his hospitalization. He also had alcohol and 
benzodiazepine dependence, but had not recently used 
those substances. He sporadically used cannabis during 
his youth. No other substances were used. The patients did 
not have any other mental or medical antecedents, or ante-
cedents of psychotic episodes. 
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Case 2
A 52-year-old male presented with a psychotic episode 
two days after hospitalization. This episode was charac-
terized by suspiciousness, partially structured reference 
and prejudice delusions, and disorganized behavior. He 
had a short time and spatial disorientation at the beginning 
of this state, followed by normal attention and conscious-
ness. Toxin screening, blood studies, and brain tomog-
raphy were performed to rule out an organic cause for the 
psychosis. BDNF levels were measured on the first day of 
hospitalization (52.82 ng/ml) and again 12 days later 
(29.93 ng/ml) as per the protocol. The initial BDNF level 
was low; the second measurement was lower than the ini-
tial measurement and coincided with the patient’s psy-
chotic symptoms. The psychotic episode was treated with 
200 mg/day quetiapine, and the psychotic symptoms were 
improved 10 days later.
No relevant antecedents were noted in his medical his-
tory (only surgical intervention for an anal abscess). 
However, the patient’s psychiatric history included the 
previous diagnosis of a cluster A personality disorder 
(PD), not specified. He had a long toxicological history; 
he only had cocaine and nicotine dependence upon clin-
ical hospitalization. He previously had heroin, cannabis, 
and alcohol dependence. There was no antecedent of psy-
chotic episodes (with or without substance use). 
DISCUSSION
Here we reported two cases with cocaine dependence 
who had initial low serum BDNF levels upon hospital-
ization that decreased further in association with psy-
chotic symptoms. Upon hospitalization, the patients were 
diagnosed with cocaine and tobacco dependence; no pre-
vious psychotic episodes (with or without substance use) 
were documented. It is important to point out that other 
causes of psychosis were ruled out in both patients 
(organic or pharmacological etiologies). It was important 
to consider the psychiatric history of both patients. In Case 
1, the patient had a previous episode of MD, which must 
be considered when interpreting the BDNF level data. MD 
disorder has been correlated with low BDNF levels, which 
were then enhanced after antidepressant treatment.20) In 
this patient, MD and psychotic episodes may have repre-
sented nervous system damage mediated by BDNF sys-
tem alterations. In Case 2, a diagnosis of cluster A PD, not 
specified, was significant because evidence exists sug-
gesting that PD could be a risk factor for psychosis con-
version in at-risk patients.21) There are few studies on the 
relationship between PD and BDNF. No studies exist on 
cluster A PD and BDNF; however, epigenetic changes in 
BDNF expression (DNA methylation) were investigated 
in patients with borderline PD,22) and one study revealed a 
higher BDNF plasma level in patients with borderline 
PD.22) Another study reported that platelet BDNF was de-
creased in males with borderline PD.23)
The cases that we presented are in line with evidence 
suggesting that BDNF may be useful as a marker not only 
of psychotic episodes or schizophrenia8,9) but also of CIP5) 
and addictive disorders.3,5) Our cases presented with an in-
itial low level of BDNF similar to other reports of patients 
with cocaine dependence3) and schizophrenia.6,8,9,24) Some 
researchers reported that the initial low levels increase un-
til they normalize during cocaine withdrawal in patients 
without a history of CIP.3,5) Furthermore, in patients who 
use crack cocaine, BDNF levels increase after crack co-
caine withdrawal.25) We did not observe an increase in 
BDNF levels following cocaine withdrawal in our cases; 
conversely, we observed a marked reduction of those lev-
els in our patients that coincided with psychotic episodes. 
BDNF reportedly decreased during the first psychotic epi-
sode,10) and was associated with the duration of the first 
psychotic episode.11) These data are interesting because 
few studies measured BDNF levels during a patient’s first 
psychotic episode, and many studies were conducted in 
patients with chronic psychosis.9) Employing BDNF as a 
biological marker could be useful in some aspects of psy-
chosis, with the best use potentially being as a prognostic 
or disease activity biomarker for psychotic episodes.1,5,8-11) 
Additionally, BDNF has been studied as a marker for dif-
ferent aspects of drug addictions (initiation, maintenance, 
abstinence, craving, risk factors) and also as a predictive 
factor for cocaine relapse.14,24) The interaction between 
BDNF and the dopaminergic system, particularly in mid-
brain dopaminergic neurons, could explain its relationship 
with drug reward and relapse.1,3,24)
Finally, there are some limitations to extrapolating 
these cases. First, patients received placebo, caffeine, or 
biperiden during the original trial. In animal models, caf-
feine increased BDNF expression. However, the BDNF 
levels did not differ among the groups (including the pla-
cebo group) in the original trial.3,5) Both patients had nic-
otine dependence. Many animal and human studies found 
that nicotine increased BDNF expression and its levels19); 
however, some findings were inconsistent.19) Specifically, 
one study showed that schizophrenic smokers had sig-
nificantly increased BDNF levels and fewer positive 
symptoms than nonsmokers.19) In our cases, BDNF levels 
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were decreased, even with nicotine use. Both patients had 
the same exercise and diet conditions, which is important 
because diet and exercise can modify BDNF expression.15,16)
BDNF is an important neuropsychiatric biomarker that 
should be investigated further; its biological functions 
could explain its important correlation with several diseases. 
The correlation between BDNF and many aspects of psy-
chotic episodes (duration, diagnosis, prognosis, etc.) 
could make it useful as a biological marker. The cases re-
ported herein suggest a correlation between BDNF de-
crease and CIP. Although we only reported two cases, and 
other factors might be related to changes in BDNF levels, 
this information could be helpful in order to elucidate 
whether BDNF could be a biological marker for CIP. 
Future research should be conducted in this area, includ-
ing specific trials that compared cocaine effects on BDNF 
levels in patients with CIP.
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